P-225Phase 3 multicenter, open-label, randomized study of...

Annals of Oncology 2019 / 07 Vol. 30; Iss. Supplement

P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial

Javle, M, Borbath, I, Clarke, S, Hitre, E, Louvet, C, Macarulla, T, Oh, D, Spratlin, J, Valle, J, Weiss, K, Berman, C, Howland, M, Ye, Y, Cho, T, Moran, S, Abou-Alfa, G
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz155.224
Date:
July, 2019
File:
PDF, 84 KB
2019
Conversion to is in progress
Conversion to is failed